Pancreatic Fistula
Grade A B C Clinical condition Well Often well Ill appearing/bad Specific treatmenta No Yes/no Yes US/CT (if obtained) Negative Negative/positive Positive Persistent drainageb (after 3 weeks) No Usually yes…
Grade A B C Clinical condition Well Often well Ill appearing/bad Specific treatmenta No Yes/no Yes US/CT (if obtained) Negative Negative/positive Positive Persistent drainageb (after 3 weeks) No Usually yes…
Fig. 24.1 Schematic cross-sectional view demonstrating the resection area of distal pancreatectomy with en bloc celiac axis resection (DP-CAR). The dotted line indicates the dissection plane. adr adrenal gland, Ao…
Total 0–14 15–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75+ Crude ASR(W) Both 337,872 0.0 0.2 1.3 3.1 6.1 10.4 16.5 24.0 32.5 55.7 4.8 4.2 Men 178,161…
Fig. 17.1 The superior mesenteric artery (SMA) and superior mesenteric vein (SMV) are identified at the infracolic mesentery. The middle colic artery is usually divided if cancer invasion is severe…
Fig. 40.1 New types of peptide-based vaccines: Examples of new types of peptide-based vaccines are shown. Gray and black boxes indicate CTL and helper T-cell epitopes, respectively 40.2 No Impact…
Trial Treatment n Median survival month) Overall survival (%) GITSG [9, 10] Chemoradiation 21 21 14 (5 years) Observation 22 10.9 4 (5 years) Chemoradiation(additional study) 30 18 46 (2…
Fig. 12.1 Magnetic resonance cholangiopancreatogram showing multiple branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) Fig. 12.2 Magnetic resonance cholangiopancreatogram demonstrating a mucinous cystic neoplasm (MCN) 12.2 Guidelines for the Management…
Fig. 11.1 Schema for initial evaluation and categorization of patients with pancreatic adenocarcinoma 11.1.4 Stratification Using MDACC Borderline Patient Types In practice, the fitness of each patient for pancreatic surgery…
Fig. 9.1 FDG PET/CT imaging of a patient with pancreatic adenocarcinoma. Primary tumor is located at uncinate process of the pancreas. Whole body projection image and PET/CT tomography reveal metastasis…
Study/authorpublication year Launched date Study design N LAPDAC (%) Gem DI (%) Median (95% CI) survival, months ORR (%) PFS OS I. Gemcitabine vs. non-gemcitabine-containing regimens in advanced pancreatic cancer…